The Administrative Core is comprised of Cancer Center Administration and Senior Leadership. Abramson Cancer Center (ACC) Administration provides centralized coordination of resources and services required to facilitate the ACC's scientific mission to reduce the burden of cancer. Coordinated activities include: participation in the governance and decision-making processes of the Center; representation of the Center within the parent Institution; and the oversight and management of multiple CCSG-related activities. CCSG- relevant activities include: support of Planning and Evaluation; oversight of Shared Resources; support of faculty recruitment; management of the membership process and data, such as publications and grants; management of the Pilot Projects Program; space management; coordination and documentation of Center meetings; budgeting and financial management; and management of the CCSG application. ACC Administration is comprised of a cohesive group of highly experienced staff with the demonstrated expertise needed to enable the ACC to realize its mission and respond to the growing research needs of the membership. These key administrative staff members have clearly defined roles, responsibilities and reporting lines, ensuring that the administrative activities of the ACC are delivered in an effective and efficient manner. ACC Administration provides vital support to the ACC Director, Senior Leadership, Program Leaders, Advisory Groups, Shared Resources and members. Senior Leadership is a carefully selected group of nationally prominent individuals who have clearly defined roles while sharing overall responsibility for realizing the mission of the ACC, developing and implementing strategies that respond to the needs of members, and fostering a creative, cohesive cancer research environment that encourages transdisciplinary team science across the translational pipeline. Leaders identify scientific issues and strategic priorities and review progress toward achieving goals. Dr. Chi Dang has served as Director since 2011, replacing Dr. Craig Thompson. Dr. Caryn Lerman has continued in her role as Deputy Director, as have Dr. Lewis Chodosh as AD for Basic Research, Dr. Garrett Brodeur as AD for Pediatric Research, Dr. Timothy Rebbeck as AD for Population Science, and Dr. James Alwine as AD for Shared Resources. Dr. Roger Cohen replaced Dr. Lynn Schuchter as AD for Clinical Research. Three new AD positions were created: Dr. Robert Vonderheide was appointed AD for Translational Research, Dr. Carmen Guerra was appointed AD for Diversity and Outreach, and Dr. Brian Keith was appointed AD for Education and Training. Mr. Robert Wynne was promoted from AD for Finance to AD for Administration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-40
Application #
8998396
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
$714,368
Indirect Cost
$267,888
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325

Showing the most recent 10 out of 1047 publications